Literature DB >> 16581063

Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

Amrita Dosanjh1.   

Abstract

Pirfenidone has a simple chemical structure, but may have profound implications for transplantation management. One of the leading causes of allograft failure is chronic allograft dysfunction, manifested by chronic inflammation and chronic fibrosis [Estenne, M., Hertz, M.I., 2002. Bronchiolitis obliterans after human lung transplantation. AJRCCM. 166, 440-444.]. This review summarizes the literature to date on Pirfenidone in the setting of transplantation, and those studies pertinent to the mechanisms of organ rejection and possible use of Pirfenidone in transplantation patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581063     DOI: 10.1016/j.ejphar.2006.03.007

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.

Authors:  Gary A Visner; Fengzhi Liu; Peyman Bizargity; Hanzhong Liu; Kaifeng Liu; Jun Yang; Liqing Wang; Wayne W Hancock
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

Review 2.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

3.  Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but Not Krebs von den Lungen-6.

Authors:  Seidai Sato; Masaki Hanibuchi; Asami Fukuya; Youhei Yabuki; Hiroki Bando; Terumi Yoshijima; Hisatsugu Goto; Hirohisa Ogawa; Yasuhiko Nishioka
Journal:  Lung       Date:  2014-06-01       Impact factor: 2.584

4.  Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients.

Authors:  Hideki Kusagaya; Yutaro Nakamura; Masato Kono; Yusuke Kaida; Shigeki Kuroishi; Noriyuki Enomoto; Tomoyuki Fujisawa; Naoki Koshimizu; Koshi Yokomura; Naoki Inui; Takafumi Suda; Thomas V Colby; Kingo Chida
Journal:  BMC Pulm Med       Date:  2012-12-05       Impact factor: 3.317

5.  Pirfenidone regulates LPS mediated activation of neutrophils.

Authors:  Shankar J Evani; S L Rajasekhar Karna; Janakiram Seshu; Kai P Leung
Journal:  Sci Rep       Date:  2020-11-17       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.